In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2

PCGF Homologs, CBX Proteins, and RYBP Define Functionally Distinct PRC1 Family Complexes

(2012) Zhonghua Gao et al.   MOLECULAR CELL

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

Expression of BMI-1 and Mel-18 in breast tissue - a diagnostic marker in patients with breast cancer

(2011) Margit LH Riis et al.   BMC CANCER

Epigenetics and B-cell lymphoma

(2011) Rita Shaknovich et al.   CURRENT OPINION IN HEMATOLOGY

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

(2010) D. B. Yap et al.   BLOOD

BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer

(2010) Xiao-Wei Zhang et al.   Molecular Cancer

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

(2010) Ryan D Morin et al.   NATURE GENETICS

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis

(2010) Cheng-Gang Wang   WORLD JOURNAL OF GASTROENTEROLOGY

Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells

(2009) Manjari Dimri et al.   CARCINOGENESIS

A Vertebrate Polycomb Response Element Governs Segmentation of the Posterior Hindbrain

(2009) Angela Sing et al.   CELL

The novel tumor-suppressor Mel-18 in prostate cancer: Its functional polymorphism, expression and clinical significance

(2009) Wei Wang et al.   INTERNATIONAL JOURNAL OF CANCER